Rubius Therapeutics, Inc(NASDAQ:RUBY) 
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematologic...
Website: http://www.rubiustx.com
Founded: 2014
Full Time Employees: 231 (May 2021)
CEO: Pablo J Cagnoni
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2023-07-05
P
O 0.02
H 0.03
L 0.02
C 0.02
V 282,150
10EMA 0.02
20EMA 0.02
60EMA 0.02
120EMA 0.02
250EMA 0.02